Roche scores clinical trial win in slowing aggressive type of breast cancer
An immunotherapy cocktail from Roche helped slow an aggressive type of breast cancer where new treatments have proven elusive.
Featured Posts
Biomarker Development: Unlocking the Promise of Cancer Immune Therapy
Emboldened by 2017’s back-to-back FDA approvals of the first drugs that use genetically engineered patient immune cells – Kymriah (tisagenlecleucel) to treat leukemia and Yescarta (axicabtagene ciloleucel) to combat large-B-cell lymphomas – immunotherapy researchers are continuing to revolutionizing cancer treatment. But uneven patient response rates and the side effects often associated with immunotherapies are putting high priority on accurately identifying which patients would benefit most from particular treatment options.
Opdivo fails to meet lung cancer study goal
Bristol-Myers Squibb’s blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.
Bristol-Myers to invest in Compugen, collaborate in clinical trials
Bristol-Myers Squibb and Israel’s Compugen will collaborate in clinical trials for patients with advanced solid tumors.
Janssen Terminates Collaboration with Aduro Biotech
Janssen Biotech informed Aduro Biotech that the Johnson & Johnson company was terminating a research and license deal related to Aduro’s Listeria treatment for cancers.
U.S. and Cuba Biopharma Venture Sees Fruit in Lung Cancer Study
A Cuban-developed lung cancer treatment combined with Bristol-Myers Squibb’s anti-PDL1 Opdivo shows promise in treating patients who would not likely benefit from immune checkpoint inhibition.
R&D Cooperation Between China and Western Pharma Companies Up 70 Percent
China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates, and western pharmaceutical companies are making greater inroads there.
Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
Seattle Genetics Inc. and Astellas Pharma Inc. announced completion of enrollment for the enfortumab vedotin EV-201 pivotal phase 2 clinical trial cohort of patients with locally advanced or metastatic urothelial cancer who have been previously treated with both platinum chemotherapy and a checkpoint inhibitor (PD-L1 or PD-1).
Opposites attract: Blurring the lines between small and large molecule manufacturing
This whitepaper assesses the current state of the large molecule sector, and how it may be able to learn from the small molecule industry in terms of its supply chain support infrastructure, as well as its acquisition of staff and the adoption of PAT.
Biomarker Development: Unlocking the Promise of Cancer Immune Therapy
Emboldened by 2017’s back-to-back FDA approvals of the first drugs that use genetically engineered patient immune cells – Kymriah (tisagenlecleucel) to treat leukemia and Yescarta (axicabtagene ciloleucel) to combat large-B-cell lymphomas – immunotherapy researchers are continuing to revolutionizing cancer treatment. But uneven patient response rates and the side effects often associated with immunotherapies are putting high priority on accurately identifying which patients would benefit most from particular treatment options.
Merck to Acquire Viralytics for $394 Million
Merck & Co. is driving forward in its quest to develop a premier immuno-oncology pipeline with the acquisition of Australia-based Viralytics Ltd. and its oncolytic immunotherapy treatments.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
October 2018 Focus: Top 50 Pharma, Company of the Year and more!